Visitors Now:
Total Visits:
Total Stories:
Profile image
By Money Morning (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Core Labs Trims 3Q Outlook – Analyst Blog

Wednesday, October 3, 2012 22:35
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Core Laboratories N.V. (CLB) cut its view for the upcoming quarter owing to lower North American rig counts.

The Amsterdam, Netherlands-based oilfield service company now expects its third quarter 2012 earnings in the band of $1.09 to $1.13 per share on the back of consolidated revenues of $240 million to $245 million.

Earlier – during its second quarter earnings release – Core Laboratories had projected earnings in a range of $1.17 to $1.25 per share and revenues of about $250 million to $260 million. It was based on a flat North American rig count, besides factoring in improving activity outside North America.

But since the end of the second quarter 2012, the U.S. land rig count of Baker Hughes Inc. (BHI) has slipped by approximately 6%, or by 112 units, with the Canadian rig count 30% below the year-ago level. This level of low activity has affected Core Laboratories' Production Enhancement segment.

Core Laboratories now expects third quarter 2012 revenue for this segment to be roughly $100 million, reflecting a minor sequential improvement.

The company anticipates activity levels for the balance of the year to be similar to the third quarter. With this, Core Laboratories would expect fourth quarter revenues and earnings to be similar to the third quarter.

Core Laboratories’ deep portfolio of proprietary products and services positions it to operate successfully in the current environment of low commodity prices and growing maturity in the global hydrocarbon reserve base. Additionally, the company’s strong presence in the emerging shale plays and its global footprint – including markets in the Middle East, Asia Pacific, and East and West Africa – facilitate steady growth rates going forward.

However, the company’s business is not immune to gas/oil price volatility, exploration and production spending patterns, costs, geo-political risks, competition and the advent of new technologies.

We expect Core Laboratories to perform in line with the broader market and, therefore, maintain our Neutral recommendation. However, the company retains a Zacks #4 Rank, which is equivalent to a Sell rating for a period of one to three months.
 

 
BAKER-HUGHES (BHI): Free Stock Analysis Report
 
CORE LABS NV (CLB): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



Source:

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.